Development of medications for the treatment of opiate and cocaine addictions : issues for the government and private sector

Author(s)

    • Fulco, Carolyn E.
    • Liverman, Catharyn T.
    • National Institute on Drug Abuse. Committee to Study Medication Development and Research
    • Institute of Medicine (U.S.). Division of Biobehavioral Sciences and Mental Disorders

Bibliographic Information

Development of medications for the treatment of opiate and cocaine addictions : issues for the government and private sector

Carolyn E. Fulco, Catharyn T. Liverman, and Laurence E. Earley, editors ; Committee to Study Medication Development and Research at the National Institute on Drug Abuse, Division of Biobehavioral Sciences and Mental Disorders, Institute of Medicine

National Academy Press, 1995

Available at  / 3 libraries

Search this Book/Journal

Note

Committee chairman: Laurence E. Earley

Support for this study was provided by the National Institute on Drug Abuse

Includes bibliographical references

Description and Table of Contents

Description

Pharmacotherapy, as a means of treating drug addiction in combination with other treatment modalities, has received too little attention from the research community, the pharmaceutical industry, public health officials, and the federal government. Medications to combat drug addiction could have an enormous impact on the medical consequences and socioeconomic problems associated with drug abuse, both for drug-dependent individuals and for American society as a whole. This book examines the current environment for and obstacles to the development of anti-addiction medications, specifically those for treating opiate and cocaine addictions, and proposes incentives for the pharmaceutical industry that would help overcome those obstacles and accelerate the development of anti-addiction medications. Table of Contents Front Matter Executive Summary 1 Introduction 2 Overview of the State of Scientific Knowledge Concerning Drug Addiction 3 Assessment of the Medications Development Division 4 Treatment Setting and Effectiveness 5 Treatment Financing and Trends in Health Insurance 6 Training and Education 7 Federal Laws and Regulations 8 State Laws and Regulations 9 Market Obstacles and Creating Incentives Appendix A: Acknowledgments Appendix B: Organization and Mission Statements of NIDA's Medications Development Division and Its Branches Appendix C: Diagnostic Criteria for Psychoactive Substance Dependence Appendix D: Survey of Pharmaceutical Companies Appendix E: Model Federal Programs in Pharmaceutical R&D Appendix F: Workshop Agenda and Participants Appendix G: Health Care Reform Legislation Appendix H: Acronyms

Table of Contents

  • 1 Front Matter
  • 2 Executive Summary
  • 3 1 Introduction
  • 4 2 Overview of the State of Scientific Knowledge Concerning Drug Addiction
  • 5 3 Assessment of the Medications Development Division
  • 6 4 Treatment Setting and Effectiveness
  • 7 5 Treatment Financing and Trends in Health Insurance
  • 8 6 Training and Education
  • 9 7 Federal Laws and Regulations
  • 10 8 State Laws and Regulations
  • 11 9 Market Obstacles and Creating Incentives
  • 12 Appendix A: Acknowledgments
  • 13 Appendix B: Organization and Mission Statements of NIDA's Medications Development Division and Its Branches
  • 14 Appendix C: Diagnostic Criteria for Psychoactive Substance Dependence
  • 15 Appendix D: Survey of Pharmaceutical Companies
  • 16 Appendix E: Model Federal Programs in Pharmaceutical R 17 Appendix F: Workshop Agenda and Participants
  • 18 Appendix G: Health Care Reform Legislation
  • 19 Appendix H: Acronyms

by "Nielsen BookData"

Details

Page Top